Shares of Iovance Biotherapeutics Inc (IOVA) are trading -7% lower at a price of $6.62 at the time of this writing. While it's generally been a cheery day for this part of the market, the company is trailing behind it's peers in the Health Care sector.
-Iovance Biotherapeutics, Inc. (IOVA) has received feedback from the Food and Drug Administration (FDA) on the rolling Biologics License Application for Lifileucel, an investigational drug for melanoma
-The FDA has requested additional data
-Shares of IOVANCE are down more than 14% as a result
Iovance Biotherapeutics Inc has been trading between a 52-week high of $20.6 and a 52-week low of $5.42. The stock has a market cap of $1.04 Billion.
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary process, and infused back into the patient.
Why Iovance Biotherapeutics Is Crashing Today
The Motley Fool 11-18-22
Iovance Biotherapeutics Pushes FDA Rolling Submission Deadline Into Next Year For Its Lead Skin Cancer Candidate
Iovance''s stock is down after receiving FDA feedback on application for new melanoma drug
Iovance Biotherapeutics Tanks as FDA Requests More Data for Lifileuel
Williams-Sonoma, Farfetch, Iovance Biotherapeutics among premarket losers'' pack
Seeking Alpha 11-18-22